Continuous and Intermittent Administration of Intravenous Sildenafil in Critically Ill Infants with Pulmonary Hypertension

2021 ◽  
Author(s):  
Chetan Sharma ◽  
Joseph Burns ◽  
Aparna Kulkarni ◽  
Jane E. Cerise ◽  
Fernando Molina Berganza ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Critically Ill ◽  
Intermittent Administration

CHARACTERISTICS AND OUTCOMES OF CRITICALLY ILL PATIENTS WITH PRECAPILLARY PULMONARY HYPERTENSION WHO UNDERGO ENDOTRACHEAL INTUBATION

CHEST Journal ◽  
2019 ◽  
Vol 156 (4) ◽  
pp. A349
Author(s):  
Kavitha Gopalratnam ◽  
Yewande Odeyemi ◽  
Nicole Andrijasevic ◽  
Jacob Jentzer ◽  
Ognjen Gajic ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Critically Ill ◽  
Endotracheal Intubation ◽  
Critically Ill Patients

Comparison of the effect of intermittent administration and continuous infusion of famotidine on gastric pH in critically ill patients

1995 ◽  
Vol 23 (4) ◽  
pp. 687-691 ◽  
Author(s):  
Ali A. Baghaie ◽  
Mojtaba Mojtahedzadeh ◽  
Robert L. Levine ◽  
&NA; Fromm Robert E. Jr ◽  
Kalpalatha K. Guntupalli ◽  
...  
Keyword(s):  
Continuous Infusion ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Gastric Ph ◽  
Intermittent Administration

Impact Of Pre-existing Pulmonary Hypertension On Survival Of Critically Ill Patients

2010 ◽  
Author(s):  
Aamir Awan ◽  
Palaniappan Manickam ◽  
Paul Kleinow ◽  
Nandini Sunkireddy ◽  
Muneer Ahmad ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Critically Ill ◽  
Critically Ill Patients

scholarly journals Pulmonary Hypertension in the Critically Ill

2008 ◽  
Vol 4 (3) ◽  
pp. 150-160
Author(s):  
Michelle Chew ◽  
Lill Bergenzaun ◽  
Hans Ohlin ◽  
Anders Ersson
Keyword(s):  
Pulmonary Hypertension ◽  
Critically Ill

scholarly journals Implication of inhaled nitric oxide for the treatment of critically ill COVID‐19 patients with pulmonary hypertension

2020 ◽  
Author(s):  
Wen‐Xia Feng ◽  
Yang Yang ◽  
Junmin Wen ◽  
Ying‐Xia Liu ◽  
Lei Liu ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Pulmonary Hypertension ◽  
Critically Ill ◽  
Inhaled Nitric Oxide

scholarly journals Efficacy and safety of vasopressin and terlipressin in preterm neonates: a protocol for a systematic review

2021 ◽  
Vol 5 (1) ◽  
pp. e001067
Author(s):  
Abdulrahman Salim Alsaadi ◽  
Katelyn Sushko ◽  
Vivian Bui ◽  
John Van Den Anker ◽  
Abdul Razak ◽  
...  
Keyword(s):  
Systematic Review ◽  
Pulmonary Hypertension ◽  
Critically Ill ◽  
Clinical Effectiveness ◽  
Persistent Pulmonary Hypertension ◽  
Preterm Neonates ◽  
Cochrane Central Register ◽  
Efficacy And Safety ◽  
Ovid Medline ◽  
Registration Number

BackgroundThe use of vasoactive agents like arginine vasopressin (AVP) and terlipressin to treat hypotension or persistent pulmonary hypertension in critically ill preterm neonates is increasing. Therefore, a systematic review of the available data on dosing, efficacy and safety of AVP and terlipressin in this patient population appears beneficial.MethodsWe will conduct a systematic review of the available evidence on the use of AVP and terlipressin for the treatment of hypotension or persistent pulmonary hypertension in preterm neonates. We will search Ovid MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Google Scholar from inception to March 2021. Two reviewers will independently screen titles and abstracts, review the full text of eligible studies, extract data, assess the risk of bias and judge the certainty of the evidence. Our primary outcome will be an (1) improvement of end-organ perfusion after initiation of AVP or terlipressin and (2) mortality prior to discharge. Our secondary outcomes will include (1) major neurosensory abnormality and (2) the occurrence of adverse events.DiscussionThe currently available evidence on the efficacy and safety of AVP and terlipressin in preterm neonates is limited. Yet, evidence on the pharmacology of these drugs and the pathophysiology of vasoplegic shock support the biological plausibility for their clinical effectiveness in this population. Therefore, we aim to address this gap concerning the use of vasopressin and terlipressin among critically ill preterm neonates.Trial registrationThis protocol has been submitted for registration to the international database of prospectively registered systematic reviews (PROSPERO, awaiting registration number).

Sign in / Sign up

Export Citation Format

Share Document